Our data also confirm previous observations performed in different experimental systems [13] showing that NG2 is not able to bind PDGF-B to influence PDGF-B-driven signaling, while they reduce the expectations on the NG2 proteoglycan as a target molecule useful to efficiently treat gliomas. The gene discussed is PDGFB; the disease is central nervous system cancer.